Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027651 (tumor)
 685,946 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A case of osteosarcoma of the right mandible is described. The patient had a long-standing fibrous dysplasia (Jaffe & Lichtenstein disease) in that area. The osteosarcoma did not respond to surgical treatment or radiation and continued to grow, causing the death of the patient. This case is of interest because of the correlation between the radiographic image and the 85Sr-uptake on a scintiscan which corresponded exactly to the tumor mass.
 ...
PMID:Correlation between bone scanning and the radiographic image in the diagnosis of osteosarcoma. 80 78

The plasma membrane of a cloned line of TE-85 (human osteosarcoma) cells subcultured for the last 4 years was isolated. The isolation was by hypotonic swelling, cell homogenization, and discontinuous sucrose gradient ultracentrifugation for 16 hr. Tumor-specific water-soluble antigens were identified by limited papain digestion of the isolated plasma membrane. Fractionation by diethylamino-ethyl anion-exchange column chromatography yielded antigenic fractions that inhibited the reaction of immune serum (from an unrelated patient with osteosarcoma) with the plasma membrane of TE-85 cells in tissue culture by indirect immunofluorescence test. Microimmunodiffusion confirmed the specificity of the isolated antigen against the sera of other patients with osteosarcoma. The definition of the antigen fraction may permit evaluation of antigen-antibody interaction in tumor immunity.
 ...
PMID:Isolation and partial purification of plasma membrane-associated antigens from human osteosarcoma (TE-85) cells in tissue culture. 82 49

After inoculating newborn W/Fu rats with adenovirus type 9, 27 of 27 females developed mammary fibroadenomas with a latency period of 14-25 weeks. No tumors were observed after inoculation with adenovirus type 5 or in males with the type 9 inoculation. After persistence of the tumors for 3-14 months, malignant transformation of the stroma resulted in different types of sarcoma in three rats: fibrosarcoma, round-cell liposarcoma, osteosarcoma and malignant mesenchymoma. In another animal the stroma of a fibroadenoma was highly cellular, suggesting a transition into fibrosarcoma. Malignant transformation of the epithelial component was not observed. Tumor cells contained adenovirus type 9-specific T-antigen, and rats with transplanted tumors were immunized to T-antigen. Mammary fibroadenomas without signs of malignant transformation developed in eight of nine female rats inoculated with adenovirus type 9 at an adult age. Neonatal thymectomy and total body x-irradiation neither significantly shortened the induction time of adenovirus 9-induced fibroadenomas nor increased the frequency of malignant transformation in females. One lipoma and one highly differentiated liposarcoma, however, appeared in two male rats. The results provide an example of the progression of a virus-induced benign tumor into a malignant neoplasm.
 ...
PMID:Studies on adenovirus type 9-induced mammary fibroadenomas in rats and their malignant transformation. 87 51

Combination chemotherapy with adriamycin and DTIC was used in 102 evaluable patients under 15 years of age who had previously treated metastatic solid tumors. Responses, defined as 50% or more reduction in all tumor masses, occurred in 10 out of 27 patients with neuroblastoma, 3 out of 8 patients with Wilms tumor, 7 out 15 patients with Ewing sarcoma, 2 out of 6 patients with osteosarcoma, 5 out of 13 patients with rhabdomyosarcoma, and 15 out of 33 patients with miscellaneous tumors which included a patient who had a complete regression of an extensive juvenile angiofibroma. Response rate to combination chemotherapy with adriamycin and DTIC in patients with Ewing sarcoma was significantly superior to the response rate obtained with adriamycin alone in another Southwest Oncology Group Study. Major toxicity included nausea, vomiting, myelosuppression, high incidence of pneumocystis carinii pneumonia (5 patients) and congestive heart failure (4 patients). There was 7 drug-associated deaths due to sepsis (1), pneumocystis carinii pneumonia (4), and congestive heart failure (2).
 ...
PMID:Combination chemotherapy with adramycin (NSC-123127) and dimethyl triazeno imidazole carboxamide (DTIC) (NSC-45388) in children with metastatic solid tumors. 95 60

One hundred thirty patients with histologically verified primary fibrosarcoma of bone, unassociated with any pre-existent benign bone condition, were treated at Memorial Sloan-Kettering Cancer Center between 1918 and 1973. This series of cases represents approximately 5% of primary malignant bone tumors treated in our institution. Eighty-nine of the lesions were medullary or central in location, and 41 were periosteal or peripheral. There was a nearly equal sex distribution, and a mean age of 38 years ranging from 4 to 83 years. This lesion exhibited a strong predilection for long bones, with the most common location being the femur (43 cases), humerus (16 cases), and tibia (12 cases). In 19 instances, bones of the head and neck area were the primary sites. The roentgenographic differential diagnoses included osteolytic osteogenic sarcoma, malignant giant cell tumor, metastatic carcinoma, or solitary plasma cell myeloma. Major ablative surgery was the primary method of therapy. Amputation was performed, yielding the best curative results in high-grade tumors, while radical local excision sufficed for most low-grade periosteal fibrosarcomas. Thirty-four percent of the patients survived 5 years (27% medullary and 52% periosteal), while 28% were alive after 10 years (20% medullary and 48% periosteal). These survival rates provide further evidence that fibrosarcoma of bone is a distinct clinicopathologic entity and not a variant of osteosarcoma, which carries a much poorer 5-year survival rate of approximately 17%.
 ...
PMID:Primary fibrosarcoma of bone. A clinicopathologic study of 130 patients. 105 40

An attempt was made to quantify the host antitumor immune response in 16 dogs with progressively growing tumors by evaluating the in vitro reactivity of their lymph node or peripheral blood lymphocytes to their own tumor cells. Serum from dogs with the same histologic type of neoplasm inhibited allogenic lymphocyte cytotoxicity, whereas serum from normal dogs, and a dog clinically free of osteosarcoma 17 months after limb amputation, did not significantly block cell-mediated reactivity. Low ratios of sensitized lymphocytes to tumor cells often stimulated tumor cell growth in vitro. Autologous serum from dogs with progressively growing neoplasms appeared to potentiate the stimulation of tumor growth above a simple blocking of lymphocyte-mediated cytotoxicity. An attempt was made to correlate the in vitro immune reactivity of the dog to the clinical behavior of its neoplasm. There was fair to good correlation in 12 dogs and no correlation in the remaining 4 dogs.
 ...
PMID:Correlation of in vitro immune response with clinical course of malignant neoplasia in dogs. 105 21

The association between osteosarcoma and growth, including altered carbohydrate metabolism has been investigated in 5 osteosarcoma patients. Serum from an adolescent osteosarcoma patient has been noted to consistently enhance 3-H-thymidine uptake in cultured chondrocytes and tumor cells. Females survive osteosarcoma more frequently than males. In vitro serum-enhanced proliferation of osteosarcoma cells is suppressed by estradiol.
 ...
PMID:Growth and hormone control mechanisms in osteosarcoma. Evidence for a new therapeutic approach. 105 28

This study was designed to evaluate the role of isotopic scanning in determining the local extension of osteosarcoma. During the period of the study, 13 patients wtih biopsy proven osteosarcomas were evaluated. The results indicated that in no case did the isotope scan demonstrate greater intramedullary extension of tumor than the routine roentgenographic examination. In addition, despite good correlation between the roentgenogram, scan, and histologic evaluation of tumor extent, all of which showed no evidence of malignancy near the area of surgery,there have been to date 3 local recurrences.
 ...
PMID:Bone scanning-osteogenic sarcoma. Correlation with surgical pathology. 105 10

A patient's immunologic response to a malignant tumor may be a major factor in determining his ultimate prognosis. An in vitro microcytotoxicity test using cultured tritiated thymidine (3HT) labeled osteosarcoma cells and autologous fibroblasts has been developed to determine the nature of this response. The role of cell mediated and serum factors has been quantitatively evaluated and the following results obtained. Osteosarcoma patients have been demonstrated to possess a normal cellular immune response which exhibits non-specific cytotoxicity in vitro. These patients can not differentiate their tumor cells from autologous fibroblasts, even though they may significantly suppress the growth of homologous tumors or fibroblasts. Serum blocking factors capable of inhibiting lymphocyte mediated cytotoxicity are occasionally noted. A reliable quantitative microcytotoxicity technique is presented which demonstrates that: (1) osteosarcoma is not due to host immuno-incompetence, (2) a common sarcoma antigen does not exist and (3) serum blocking factors may occasionally be present.
 ...
PMID:The host immune response in human osteosarcoma. 105 66

The treatment of patients with osteosarcoma continues to result in few survivors despite advances in surgery and radiotherapy. Since the primary site of failure is pulmonary, it is apparent that a systemically active adjuvant must be employed if a cure is to be achieved. Because of the experimental evidence for an immune response against osteosarcoma and because of the potential systemic activity of the immune system, a trial of postoperative adjuvant immunotherapy was begun. Seventeen patients received immunotherapy consisting of BCG and an allogeneic tumor cell vaccine following surgical removal of all gross tumors. Eighteen per cent (3/17) of the patients who received immunotherapy remained alive and free of disease compared to 0/12 who did not. An analysis of the 14 patients with recurrence, revealed that the median time to recurrence was 3.0 months in both groups. It is, therefore, apparent that at the time of initiation of immunotherapy subclinical metastasis must already have been present. Therefore, on the basis of this study we conclude that adjuvant chemotherapy should be employed to further reduce the tumor cell burden in order for immunotherapy to be effective for osteosarcoma.
 ...
PMID:Osteosarcoma. Results of treatment employing adjuvant immunotherapy. 105 67


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>